NASH: A glance at the landscape of pharmacological treatment
Journal Title: Annals of Hepatology - Year 2016, Vol 15, Issue 5
Abstract
The role of nonalcoholic fatty liver disease, namely nonalcoholic steatohepatitis (NASH), as risk factor for liver- and non-liver-related morbidity and mortality has been extensively reported. In addition to lifestyle changes, capable of removing the metabolic factors driving disease progression, there is an urgent need for drugs able to reduce hepatic necroinflammation without worsening of fibrosis. This goal is considered by regulatory agencies as surrogate marker to define the effectiveness in pharmacological compounds in NASH, and fast-track approval was granted by the Food and Drug Administration in consideration of disease severity and unmet medical needs. Several compounds are in the pipeline of pharmaceutical industries and are being studied in phase II trials, but only a few (obeticholic acid, elafibranor) have started phase III trials. This concise review is intended to offer a systematic analysis of the most promising therapeutic intervention in NASH. In conclusion, there is reasonable expectation that drug may help curb the burden of NASH, and we look forward to obtaining solid data on their long-term safety and effectiveness. However, we should not forget that behavioral interventions remain a mandatory background treatment, able to stop disease progression in compliant overweight/ obese patients, with results that compare favorably with - and add to - the beneficial effects of drug treatment.
Authors and Affiliations
Lucia Brodosi, Francesca Marchignoli, Maria Petroni, Giulio Marchesini
Keywords
Related Articles
- EP ID EP78611
- DOI 10.5604/16652681.1212318
- Views 123
- Downloads 0
Primary prophylaxis with ciprofloxacin in cirrhotic patients with ascites: a randomized, double blind study
Introduction and aim. There is scarce information about primary prophylaxis in cirrhotic patients. The aim was to assess the efficacy of ciprofloxacin for primary prophylaxis for bacterial infections in patients with cir...
Fighting Mortality in the Waiting List: Liver Transplantation in North America, Europe, and Asia
Liver disease is a major cause of mortality worldwide. Liver transplantation (LT) is the most effective treatment for end stage liver disease. Available resources and social circumstances have led to different ways of im...
A comment from the Editor
Epidemiology of HCV infection in Latin America
Hepatitis C virus is one of the most common causes of chronic liver disease and one of the principal indications for liver transplantation. The prevalence and incidence worldwide is variable, although there may be some s...
Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy
Hyperammonemia and associated cerebral edema cause neurological abnormalities in liver disease patients. Although only 15% of ammonia production originates in the colon, management strategies for hepatic encephalopathy (...